Aastrom Biosciences Inc  

(Public, NASDAQ:ASTM)   Watch this stock  
Find more results for ASTM
3.24
-0.10 (-2.99%)
Jul 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.22 - 3.32
52 week 3.09 - 17.79
Open 3.31
Vol / Avg. 57,367.00/168,881.00
Mkt cap 21.05M
P/E     -
Div/yield     -
EPS -5.06
Shares 6.50M
Beta 0.97
Inst. own 9%
Aug 4, 2014
Q2 2014 Aastrom Biosciences Earnings Release (Estimated) Add to calendar
Jun 16, 2014
Aastrom Biosciences Inc Conference Call to discuss the Recently Acquired Cell Therapy and Regenerative Medicine Business
May 15, 2014
Q1 2014 Aastrom Biosciences Earnings Conference Call
May 15, 2014
Q1 2014 Aastrom Biosciences Earnings Release
May 7, 2014
Aastrom Biosciences 2014 Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin - -82221.05%
Operating margin - -110336.80%
EBITD margin - -107763.20%
Return on average assets -251.88% -128.09%
Return on average equity - -
Employees 40 -
CDP Score - -

Address

24 FRANKL LLOYD WRIGHT DR, PO Box 376
ANN ARBOR, MI 48106
United States - Map
+1-734-9305555 (Phone)
+1-734-6650485 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aastrom Biosciences, Inc. (Aastrom) is a development-stage company. The Company is a regenerative medicine company focused on the development of cell therapies to repair or regenerate damaged or diseased tissues. The Company is developing patient-specific, expanded multicellular therapies for use in the treatment of severe, chronic ischemic cardiovascular diseases. The Company�s cell-manufacturing technology enables the manufacture of multicellular therapies, expanded from an adult patient�s own bone marrow, to be delivered directly to damage tissues. In March 2013, it announced strategic change in research and development programs to focus on the clinical development of lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy (DCM). In June 2014, the Company acquired Sanofi's cell therapy and regenerative medicine (CTRM) business unit.

Officers and directors

Robert L. Zerbe M.D. Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Dominick C. Colangelo President, Chief Executive Officer, Chief Accounting Officer, Treasurer, Director
Bio & Compensation  - Reuters
Gerard J. Michel Chief Financial Officer, Vice President - Corporate Development
Age: 51
Bio & Compensation  - Reuters
Daniel R. Orlando Chief Operating Officer, Chief Business Officer, Chief Commercial Officer
Age: 47
Bio & Compensation  - Reuters
Ross Tubo Chief Scientific Officer
Bio & Compensation  - Reuters
David Recker Chief Medical Officer
Bio & Compensation  - Reuters
Heidi Hagen Director
Bio & Compensation  - Reuters
Timothy M. Mayleben Director
Age: 53
Bio & Compensation  - Reuters
Alan L. Rubino Independent Director
Age: 58
Bio & Compensation  - Reuters
Nelson M. Sims Independent Director
Age: 65
Bio & Compensation  - Reuters